Trial Profile
Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Perifosine (Primary) ; Temsirolimus (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2021 Status changed from discontinued to completed.
- 31 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 05 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jul 2016as reported by ClinicalTrials.gov record.